State Board of Administration of Florida Retirement System reduced its position in QuidelOrtho Co. (NASDAQ:QDEL – Get Rating) by 3.0% in the 2nd quarter, Holdings Channel reports. The fund owned 43,848 shares of the company’s stock after selling 1,372 shares during the period. State Board of Administration of Florida Retirement System’s holdings in QuidelOrtho were worth $4,261,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the stock. New Century Advisors LLC boosted its holdings in shares of QuidelOrtho by 52.6% in the 2nd quarter. New Century Advisors LLC now owns 351 shares of the company’s stock valued at $34,000 after purchasing an additional 121 shares during the last quarter. Oppenheimer & Co. Inc. boosted its holdings in shares of QuidelOrtho by 5.5% in the 1st quarter. Oppenheimer & Co. Inc. now owns 2,797 shares of the company’s stock valued at $315,000 after purchasing an additional 146 shares during the last quarter. Gladius Capital Management LP boosted its holdings in shares of QuidelOrtho by 21.0% in the 1st quarter. Gladius Capital Management LP now owns 880 shares of the company’s stock valued at $99,000 after purchasing an additional 153 shares during the last quarter. US Bancorp DE boosted its holdings in shares of QuidelOrtho by 11.4% in the 2nd quarter. US Bancorp DE now owns 1,609 shares of the company’s stock valued at $156,000 after purchasing an additional 165 shares during the last quarter. Finally, Lindenwold Advisors boosted its holdings in shares of QuidelOrtho by 6.2% in the 1st quarter. Lindenwold Advisors now owns 3,092 shares of the company’s stock valued at $348,000 after purchasing an additional 181 shares during the last quarter. Institutional investors and hedge funds own 87.20% of the company’s stock.
QuidelOrtho Stock Performance
Shares of QDEL stock opened at $93.35 on Monday. QuidelOrtho Co. has a 12 month low of $66.88 and a 12 month high of $180.06. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.66 and a quick ratio of 1.15. The firm has a market capitalization of $6.17 billion, a P/E ratio of 4.97 and a beta of 0.28. The company’s fifty day moving average price is $79.95 and its two-hundred day moving average price is $90.54.
Analyst Upgrades and Downgrades
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
- Get a free copy of the StockNews.com research report on QuidelOrtho (QDEL)
- Alphabet Stock Offers a Rare Buying Opportunity
- Walt Disney Stock is Set to Reset Expectations
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
- S&P 500 Component DexCom Set For Further Price, Earnings Growth
- MarketBeat: Week in Review 11/7 – 11/11
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.